The effects of PRAL on ACC/AHA ASCVD risk showed no significant difference in patients categorized by hypertension, by age or by overweight (hypertension; P = 0.345, age; P = 0.112, overweight; P = 0.150, respectively, for interaction). This evidence concerns the gene PRAL and hypertensive disorder.